AKRO Akero Therapeutics Inc
Price (delayed)
$45.85
Market cap
$3.65B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.75
Enterprise value
$3.35B
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein,
Highlights
AKRO's equity is up by 40% year-on-year
Akero Therapeutics's quick ratio has decreased by 35% YoY but it has increased by 13% QoQ
AKRO's net income has shrunk by 66% YoY and by 6% QoQ
AKRO's debt is up by 39% year-on-year
Key stats
What are the main financial stats of AKRO
Market
Valuations
Earnings
Shares outstanding
79.62M
Market cap
$3.65B
Enterprise value
$3.35B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.27
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$285.42M
Net income
-$252.06M
EBIT
-$247.39M
EBITDA
-$247.12M
Free cash flow
-$230.11M
Per share
Balance sheet
Liquidity
EPS
-$3.75
EPS diluted
-$3.75
Free cash flow per share
-$3.43
Book value per share
$10.75
Revenue per share
$0
TBVPS
$12.3
Total assets
$825.89M
Total liabilities
$75.77M
Debt
$35.83M
Equity
$750.11M
Working capital
$730.63M
Debt to equity
0.05
Current ratio
19.38
Quick ratio
18.69
Net debt/EBITDA
1.23
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.5%
Return on equity
-32.2%
Return on invested capital
-54.1%
Return on capital employed
-31.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKRO stock price
How has the Akero Therapeutics stock price performed over time
Intraday
4.63%
1 week
1.6%
1 month
-7.26%
1 year
61.1%
YTD
64.81%
QTD
64.81%
Financial performance
How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$285.42M
Net income
-$252.06M
Gross margin
N/A
Net margin
N/A
AKRO's net income has shrunk by 66% YoY and by 6% QoQ
Akero Therapeutics's operating income has plunged by 65% YoY and by 6% from the previous quarter
Growth
What is Akero Therapeutics's growth rate over time
Valuation
What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
4.27
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has decreased by 30% YoY
The stock's P/B is 86% above its last 4 quarters average of 2.3 and 9% above its 5-year quarterly average of 3.9
AKRO's equity is up by 40% year-on-year
Efficiency
How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on equity has decreased by 8% YoY
The ROA has contracted by 8% YoY
Akero Therapeutics's return on invested capital has increased by 5% YoY
Dividends
What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKRO.
Financial health
How did Akero Therapeutics financials performed over time
The total liabilities has soared by 69% year-on-year but it is down by 4.4% since the previous quarter
The company's total assets rose by 42% YoY
AKRO's debt is 95% smaller than its equity
AKRO's equity is up by 40% year-on-year
AKRO's debt is up by 39% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.